Insmed Incorporated (INSM)
| Market Cap | 23.19B +24.2% |
| Revenue (ttm) | 819.56M +115.1% |
| Net Income | -1.18B |
| EPS | -5.70 |
| Shares Out | 216.75M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 40,698 |
| Open | 107.51 |
| Previous Close | 107.02 |
| Day's Range | 107.00 - 108.20 |
| 52-Week Range | 90.39 - 212.75 |
| Beta | 0.78 |
| Analysts | Strong Buy |
| Price Target | 196.18 (+83.35%) |
| Earnings Date | Aug 6, 2026 |
About INSM
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 ... [Read more]
Financial Performance
In 2025, Insmed's revenue was $606.42 million, an increase of 66.73% compared to the previous year's $363.71 million. Losses were -$1.28 billion, 39.7% more than in 2024.
Financial StatementsAnalyst Summary
According to 23 analysts, the average rating for INSM stock is "Strong Buy." The 12-month stock price target is $196.18, which is an increase of 83.35% from the latest price.
News
Insmed initiated with an Outperform at BMO Capital
BMO Capital analyst Conor MacKay initiated coverage of Insmed (INSM) with an Outperform rating and $192 price target The firm’s positive view is based on Brinsupri’s rapid launch in NCFB,…
Insmed Transcript: Study result
The 12-month open-label extension of TPIP in PAH patients showed sustained and clinically meaningful improvements in exercise capacity, cardiac biomarkers, and risk scores, with a favorable safety profile even at high doses. Over 25% achieved asymptomatic status, and 65% reached refined low-risk, supporting TPIP's potential as a leading PAH therapy.
Insmed Press release: Study result
Insmed issued a press release on July 16, 2026, disclosing material business information to investors.
Insmed Slides: Study result
Insmed has posted slides in relation to its latest quarterly earnings report, which was published on July 16, 2026.
Insmed’s inhalation powder shows efficacy and safety in arterial hypertension
Insmed (INSM) announced positive 12-Month data from the ongoing open-label extension study evaluating treprostinil palmitil inhalation powder, or TPIP, administered once daily in patients with pulmona...
Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension
– 12-Month Data Demonstrated Sustained Improvement with TPIP Across All Secondary Efficacy Measures Including Reduction in Mortality Risk Status by REVEAL Lite 2.0– –Placebo Crossed Group Demonstrated...
Insmed price target raised to $161 from $160 at Wells Fargo
Wells Fargo raised the firm’s price target on Insmed (INSM) to $161 from $160 and keeps an Overweight rating on the shares. The stock appears oversold on Brinsupri discontinuation concerns,…
EMBARC Announces Its Intention to Collaborate with Insmed on Landmark Interventional Study Evaluating Disease Modification Potential of Brensocatib in Bronchiectasis
Hannover, Germany, June 25, 2026 (GLOBE NEWSWIRE) -- EMBARC Announces Its Intention to Collaborate with Insmed on Landmark Interventional Study Evaluating Disease Modification Potential of Brensocatib...
Insmed Appoints Samuele Butera as Senior Vice President, General Manager, Global Respiratory
BRIDGEWATER, N.J., June 23, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform...
The Qs Shift Gears: Nasdaq 100 Rebalances While SpaceX Looms
The Nasdaq 100 implemented its June quarterly rebalance, which shifts the tide for “the Qs.” Namely, the Invesco QQQ Trust (QQQ) and its cost-efficient sibling, the Invesco Nasdaq 100 ETF (QQQM).
Mizuho cuts Insmed target, sees buying opportunity after selloff
Mizuho lowered the firm’s price target on Insmed (INSM) to $192 from $202 and keeps an Outperform rating on the shares. The firm finds it “shocking” how quickly investor sentiment…
Insmed Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
BRINSUPRI’s launch is exceeding benchmarks, with strong physician engagement and a robust support program driving persistence. Expansion into comorbid populations and upcoming launches in Japan are expected to fuel further growth, while a diverse pipeline and prudent financial strategy position the company for sustained success.
Insmed stock price decline a ‘buying opportunity’, says Roth Capital
Roth Capital keeps a Buy rating and a $212 price target on Insmed (INSM). The 10% decline in the stock on Friday is a buying opportunity with a move driven…
Insmed price target lowered to $179 from $180 at JPMorgan
JPMorgan lowered the firm’s price target on Insmed (INSM) to $179 from $180 and keeps an Overweight rating on the shares. The firm attributes the recent selloff to the expectation…
Insmed price target lowered to $195 from $205 at RBC Capital
RBC Capital lowered the firm’s price target on Insmed (INSM) to $195 from $205 but keeps an Outperform rating on the shares. The stock has seen positive momentum, but the…
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., June 4, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform ...
Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference
BRIDGEWATER, N.J., May 27, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform ...
Insmed Transcript: RBC Capital Markets Global Healthcare Conference 2026
Strong quarterly growth and operational execution support a $1B+ revenue target, with high payer approval and patient retention. Market expansion is driven by education, new patient identification, and robust pipeline progress, including ARIKAYCE and TPIP.
Insmed Slides: Investor presentation
Insmed has posted slides in relation to its latest quarterly earnings report, which was published on May 16, 2026.
Insmed Transcript: AGM 2026
The meeting established a quorum and proceeded with the election of two directors, approval of executive compensation, and ratification of the auditor. All proposals passed with no shareholder questions submitted.
Insmed Transcript: Bank of America Global Healthcare Conference 2026
BRINSUPRI's launch is exceeding expectations with strong sales, high physician engagement, and expanding market size. Pipeline progress, especially with TPIP, and disciplined research investments position the company for sustained growth and future profitability.
Insmed Earnings Call Transcript: Q1 2026
BRINSUPRI delivered exceptional sequential growth and is on track for $1B+ in 2026 revenue, with strong payer access, high compliance, and expanding prescriber base. ARIKAYCE and TPIP also advanced, while robust cash reserves support continued execution and pipeline growth.
Insmed Quarterly report: Q1 2026
Insmed has published its Q1 2026 quarterly earnings report on May 7, 2026.
Insmed Slides: Q1 2026
Insmed has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Insmed Earnings release: Q1 2026
Insmed released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.